Published in Lancet on February 01, 1975
Malignant lymphomas--a conceptual understanding of morphologic diversity. A review. Am J Pathol (1979) 1.30
Pancreatic lymphoma. Is surgery mandatory for diagnosis or treatment? Ann Surg (1989) 1.27
Colorectal lymphoma. Clin Colon Rectal Surg (2006) 1.18
The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol (1984) 1.12
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases. J Clin Invest (1984) 1.03
Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer (1993) 0.95
Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification. Br J Cancer (1983) 0.88
Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer (1993) 0.88
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol (2014) 0.88
Dual parameter flow cytometry studies in human lymphomas. J Clin Invest (1980) 0.87
Non-Hodgkin's lymphomas. Can Med Assoc J (1978) 0.86
My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc (2012) 0.85
Microvascular closure in malignant histiocytosis. Can Med Assoc J (1979) 0.85
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol (2015) 0.81
Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma. Br J Cancer (1991) 0.80
Assessment of the evolution of cancer treatment therapies. Cancers (Basel) (2011) 0.80
A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party. Br J Cancer (1991) 0.78
Modelling lymphoma therapy and outcome. Bull Math Biol (2013) 0.76
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag (2007) 0.76
Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ (2016) 0.75
Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy. Can Med Assoc J (1982) 0.75
Lymphomania. Non-Hodgkin's lymphoma as possibly viewed through the eyes of Lewis Carroll. J R Soc Med (1987) 0.75
Failure of conventional chemotherapy in aggressive lymphomas. Postgrad Med J (1987) 0.75
Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma. CMAJ (1987) 0.75
A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos Univ Med J (2015) 0.75
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab (2017) 0.75
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol (1991) 4.22
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69
Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med (1975) 3.36
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 2.42
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). A study of 196 autopsy cases. Am J Cardiol (1968) 2.23
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Cancer of the breast: the past decade (first of two parts). N Engl J Med (1980) 2.14
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Clinical pharmacology of cyclophosphamide. Cancer Res (1973) 2.08
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Clinically defined vascular depression. Am J Psychiatry (1997) 2.06
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol (1997) 2.02
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
TB testing. Vet Rec (1996) 2.01
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92
A computer data base for information on cancer treatment. N Engl J Med (1987) 1.92
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78
Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Pseudohyperkalemia due to release of potassium from white blood cells during clotting. N Engl J Med (1966) 1.73
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med (1971) 1.65
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol (1984) 1.55
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Disability in geriatric depression. Am J Psychiatry (1996) 1.55
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer (1981) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
The cellular biology of the Reed-Sternberg cell. Blood (1994) 1.50
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Sarcoidosis in Washington, D. C. Clinical observations in 105 black patients. Arch Intern Med (1970) 1.49
Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med (1972) 1.49
Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol (1975) 1.49
Use of the Cornell scale in nondemented patients. J Am Geriatr Soc (1988) 1.48
Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med (1980) 1.48
A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer (1972) 1.46
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med (1972) 1.44
Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J Infect Dis (1989) 1.44
Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol (1991) 1.44
High-dose cisplatin in hypertonic saline. Ann Intern Med (1984) 1.43
The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med (1973) 1.43
Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis (1981) 1.42
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Recovery in geriatric depression. Arch Gen Psychiatry (1996) 1.41
Who should pay for clinical research? J Clin Oncol (1990) 1.41
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol (1984) 1.41
Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci (1974) 1.40
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med (1972) 1.40
Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res (1971) 1.38
Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med (1983) 1.38
Antibiotic growth promoters. Vet Rec (2003) 1.38
CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg (1982) 1.38
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37